Market revenue in 2023 | USD 174.8 million |
Market revenue in 2030 | USD 91.7 million |
Growth rate | -8.8% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care |
Key market players worldwide | Becton Dickinson & Co, BioMerieux SA, Bio-Rad Laboratories Inc, Abbott Laboratories, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Roche Holding AG, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 47.48% in 2023. Horizon Databook has segmented the Thailand molecular diagnostics market based on hospitals, outpatient facilities, home care covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing government initiatives to cover the cost of diagnosing and treating diseases such as cancer are expected to encourage low-income groups to seek help, improving the demand for molecular diagnostics. In May 2023, Tianlong collaborated with public hospitals in northern Thailand to improve hepatitis C and hepatitis B viral detection methods as well as early diagnosis & treatment.
The early diagnosis and effective treatment by Tianlong's HCV and HBV detection solution can aid in curbing the spread of the disease. Thailand's state hospitals have successfully implemented Tianlong's HCV & HBV detection system, and more regional hospitals are expected to do the same. In addition, in January 2023, Thailand Food and Drug Administration ("Thai FDA") approved Genetic Analysis AS for the GA-map Dysbiosis Test in Thailand.
Genetic Analysis can now offer its gut microbiome testing platform to the Thai market to meet the increasing interest and advance the awareness of dysbiosis. Furthermore, Thailand has a rapidly aging population, and as per the Economic Research Institute for ASEAN and East Asia (ERIA) in 2021, the country's aging population is growing.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Thailand molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account